ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
about
"Stormy waters ahead": global emergence of carbapenemasesEmergence of Klebsiella pneumoniae carbapenemase-producing bacteriaStrategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infectionsTargeting Antibiotic ResistanceA structural, epidemiological & genetic overview of Klebsiella pneumoniae carbapenemases (KPCs)Clinical management of infections caused by multidrug-resistant EnterobacteriaceaeIn vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.New trends in aminoglycosides use.Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.Therapy of Infections due to Carbapenem-Resistant Gram-Negative PathogensCarbapenem-resistant Enterobacteriaceae: a review of treatment and outcomesAminoglycoside modifying enzymes.Investigational antimicrobial agents of 2013.Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility.Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniaeActivity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjectsOptimization of aminoglycoside therapy.Structural and molecular basis for resistance to aminoglycoside antibiotics by the adenylyltransferase ANT(2″)-IaActivity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.Pipeline of Known Chemical Classes of Antibiotics.A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosidesRise and dissemination of aminoglycoside resistance: the aac(6')-Ib paradigm.Understanding and overcoming aminoglycoside resistance caused by N-6'-acetyltransferase.In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Crystal structure and specific binding mode of sisomicin to the bacterial ribosomal decoding site.Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.Enzymatic quorum quenching increases antibiotic susceptibility of multidrug resistant Pseudomonas aeruginosaIn vitro antimicrobial susceptibility to isepamicin of 6,296 Enterobacteriaceae clinical isolates collected at a tertiary care university hospital in Greece.New Delhi metallo-β-lactamase and multidrug resistance: a global SOS?Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: A Multicenter, Randomized, Double-Blind, Phase 2 Study.Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant
P2860
Q21131125-AE75D8E4-007D-432E-9207-2C92E2FEF16EQ24618178-35BBCA24-2E9C-4C2B-ADA1-25A23CD92106Q26859978-DD8C04E8-8234-492D-93CE-FB333934B806Q28078130-AD79918C-7E13-41B5-9C8A-CE5777447AA2Q28078638-BEB6AA28-49C8-4FAC-BAA9-CDBCC1288BC6Q28246841-897B91BD-15AA-4E03-BE2D-7343927288F9Q33558996-29F1B598-188F-4FAB-AEA8-875EA4B3F6B9Q33951177-03A8B3DB-BBE9-45FD-909B-4EFE316B459EQ34058006-C7D3657F-0FBD-4AAA-ABEF-C77D949C1B15Q34303970-6321F589-97E9-4001-B5DA-15080F6EE73CQ34320945-930562C3-4BA3-4C1B-9DE5-C6B4DBFAEC33Q34354185-C1353A27-BFA7-424E-93EE-304009CFA202Q34375204-5C49B9C5-9356-46FB-A398-9BF0D86CBEFCQ34433108-278E8876-4CEB-4B4C-AD19-D5CECC68EC16Q34483491-66EDA402-E27B-47B3-98C2-B80018B01DA6Q34625178-04ADE088-974E-4736-8184-4908A689D29DQ34632230-B5B1C743-5C5A-4E89-9318-66109BD6281CQ35005127-14B35A41-E236-4659-9B6D-6339026C30ACQ35038252-51EDB2C5-06DC-4156-8F74-F087CBD4A9F8Q36107990-2E687CA2-CEC6-4929-8DA4-D3F976E8E37CQ36683409-FE4063F9-3726-49D0-BEA2-5A835C56A989Q36726249-62B80435-A536-4910-9D8E-D5601EF6367AQ36850490-FBE66EF9-95BD-4DA3-95B9-A707F1225A04Q37528001-917B06EF-30E2-4B9F-9757-E48AFF15A558Q37712980-640F218F-1F7C-4F7D-BCCA-EA6E18A8CD91Q38944862-9A5BFC12-3FE1-4670-A35C-4B3271BC87FFQ39736448-E16F99B8-46B7-40B2-870C-6FEB8BD2043AQ40336352-18EDFF0C-1F72-444C-962E-C6E53DBB7CA9Q41130527-E8F24060-D9F3-40D5-935F-7823EBAE0E56Q41972475-A37FAC86-E946-4D6F-83B3-150CBB5E99DEQ44293892-F29337DF-6CC2-4128-BB2F-17A881252095Q49598865-1AC60767-DC7F-430E-811F-43C61CA7574BQ58746821-4BA6459F-C416-42E2-8E7B-063A987DB42E
P2860
ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ACHN-490, a neoglycoside with ...... lebsiella pneumoniae isolates.
@en
ACHN-490, a neoglycoside with ...... lebsiella pneumoniae isolates.
@nl
type
label
ACHN-490, a neoglycoside with ...... lebsiella pneumoniae isolates.
@en
ACHN-490, a neoglycoside with ...... lebsiella pneumoniae isolates.
@nl
prefLabel
ACHN-490, a neoglycoside with ...... lebsiella pneumoniae isolates.
@en
ACHN-490, a neoglycoside with ...... lebsiella pneumoniae isolates.
@nl
P2093
P2860
P356
P1476
ACHN-490, a neoglycoside with ...... lebsiella pneumoniae isolates.
@en
P2093
Andrea Endimiani
Eliana S Armstrong
James B Aggen
Kristine M Hujer
Yuvraj Choudhary
P2860
P304
P356
10.1128/AAC.00556-09
P407
P577
2009-10-01T00:00:00Z